Skip to Main Content

Author Details

Stefan Knapp
Institute of Pharmaceutical Chemistry, Goethe University
1983
476
91
Andrej Sali (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36736152Discovery of potent Plasmodium falciparum protein kinase 6 (PfPK6) inhibitors with a type II inhibitor pharmacophore.Eur J Med Chem2023
37489084Colorectal Cancer Organoid-Stroma Biobank Allows Subtype-Specific Assessment of Individualized Therapy Responses.Cancer Discov2023
37558942Characterization of Cellular Viability Using Label-Free Brightfield Live-Cell Imaging.Methods Mol Biol2023
37558941Annotation of the Effect of Chemogenomic Compounds on Cell Health Using High-Content Microscopy in Live-Cell Mode.Methods Mol Biol2023
37558940Quality Control of Chemogenomic Library Using LC-MS.Methods Mol Biol2023
37487467Leucettinibs, a Class of DYRK/CLK Kinase Inhibitors Inspired by the Marine Sponge Natural Product Leucettamine B.J Med Chem2023
37857821Structure of LRRK1 and mechanisms of autoinhibition and activation.Nat Struct Mol Biol2023
37800327Disrupted Binding of Cystathionine γ-Lyase to p53 Promotes Endothelial Senescence.Circ Res2023
37797617A machine learning and live-cell imaging tool kit uncovers small molecules induced phospholipidosis.Cell Chem Biol2023
38067641Synthesis and Biological Evaluation of 2-Substituted Quinazolin-4(3<i>H</i>)-Ones with Antiproliferative Activities.Molecules2023
38009092SGC-CLK-1: A chemical probe for the Cdc2-like kinases CLK1, CLK2, and CLK4.Curr Res Chem Biol2023
37845552Improving data quality in chemical biology.Nat Chem Biol2023
38051674Chemical, Biochemical, Cellular, and Physiological Characterization of Leucettinib-21, a Down Syndrome and Alzheimer's Disease Drug Candidate.J Med Chem2023
38047771Death by a thousand cuts through kinase inhibitor combinations that maximize selectivity and enable rational multitargeting.Elife2023
37828008DARPins detect the formation of hetero-tetramers of p63 and p73 in epithelial tissues and in squamous cell carcinoma.Cell Death Dis2023
374955675-Iodotubercidin sensitizes cells to RIPK1-dependent necroptosis by interfering with NFκB signaling.Cell Death Discov2023
37354907Tracking the PROTAC degradation pathway in living cells highlights the importance of ternary complex measurement for PROTAC optimization.Cell Chem Biol2023
37253421Structural insights into a regulatory mechanism of FIR RRM1-FUSE interaction.Open Biol2023
37385602Targeting the Alternative Vitamin E Metabolite Binding Site Enables Noncanonical PPARγ Modulation.J Am Chem Soc2023
37312836Design and Synthesis of Pyrazole-Based Macrocyclic Kinase Inhibitors Targeting BMPR2.ACS Med Chem Lett2023
36944371Deep Annotation of Donated Chemical Probes (DCP) in Organotypic Human Liver Cultures and Patient-Derived Organoids from Tumor and Normal Colorectum.ACS Chem Biol2023
37439113Deciphering the mitophagy receptor network identifies a crucial role for OPTN (optineurin) in acute myeloid leukemia.Autophagy2023
37204207Structure-Based Development of Isoform-Selective Inhibitors of Casein Kinase 1ε vs Casein Kinase 1δ.J Med Chem2023
37360399Target 2035 - an update on private sector contributions.RSC Med Chem2023
37296900Mutation in the Common Docking Domain Affects MAP Kinase ERK2 Catalysis and Stability.Cancers (Basel)2023
37094449Shifting the selectivity of pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors towards the salt-inducible kinase (SIK) subfamily.Eur J Med Chem2023
36625768Discovery of Potent and Exquisitely Selective Inhibitors of Kinase CK1 with Tunable Isoform Selectivity.Angew Chem Int Ed Engl2023
36516476MSC-1186, a Highly Selective Pan-SRPK Inhibitor Based on an Exceptionally Decorated Benzimidazole-Pyrimidine Core.J Med Chem2023
36780422Toward effective Atg8-based ATTECs: Approaches and perspectives.J Cell Biochem2023
36878151Design, synthesis and characterisation of a novel type II B-RAF paradox breaker inhibitor.Eur J Med Chem2023
36580549Development of a Potent Cyclic Peptide Inhibitor of the nNOS/PSD-95 Interaction.J Med Chem2023
36913879Oxazolo[5,4-f]quinoxaline-type selective inhibitors of glycogen synthase kinase-3α (GSK-3α): Development and impact on temozolomide treatment of glioblastoma cells.Bioorg Chem2023
36873168Chemistry-led investigations into the mode of action of NAMPT activators, resulting in the discovery of non-pyridyl class NAMPT activators.Acta Pharm Sin B2023
36711619Death by a Thousand Cuts â⿬" Combining Kinase Inhibitors for Selective Target Inhibition and Rational Polypharmacology.bioRxiv2023
36709803Epigenetic modulation by targeting bromodomain containing protein 9 (BRD9): Its therapeutic potential and selective inhibition.Int J Biol Macromol2023
34213342Addressing a Trapped High-Energy Water: Design and Synthesis of Highly Potent Pyrimidoindole-Based Glycogen Synthase Kinase-3β Inhibitors.J Med Chem2022
35608370Illuminating the Dark: Highly Selective Inhibition of Serine/Threonine Kinase 17A with Pyrazolo[1,5-<i>a</i>]pyrimidine-Based Macrocycles.J Med Chem2022
35462054BET bromodomain inhibitors.Curr Opin Chem Biol2022
35721509A Toolbox for the Generation of Chemical Probes for Baculovirus IAP Repeat Containing Proteins.Front Cell Dev Biol2022
35525558Enabling pseudokinases as potential drug targets.Methods Enzymol2022
35717504Designed Ankyrin Repeat Proteins as a tool box for analyzing p63.Cell Death Differ2022
35688808Author Correction: Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation.Nat Commun2022
35562082Calcium/calmodulin-dependent protein kinase kinase 2 regulates hepatic fuel metabolism.Mol Metab2022
35447555Synthesis and biological evaluation of Haspin inhibitors: Kinase inhibitory potency and cellular activity.Eur J Med Chem2022
35353987Kinase domain autophosphorylation rewires the activity and substrate specificity of CK1 enzymes.Mol Cell2022
36499165Discovery of 3-Amino-1<i>H</i>-pyrazole-Based Kinase Inhibitors to Illuminate the Understudied PCTAIRE Family.Int J Mol Sci2022
36104565CDK11 regulates pre-mRNA splicing by phosphorylation of SF3B1.Nature2022
36040231PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain.Biochem J2022
36136092Development and Characterization of Type I, Type II, and Type III LIM-Kinase Chemical Probes.J Med Chem2022
36098557Identification of Histone Peptide Binding Specificity and Small-Molecule Ligands for the TRIM33α and TRIM33β Bromodomains.ACS Chem Biol2022
  • 1 - 50 of 476

Recommended Authors

Cardiovascular Research Institute, University of California San Francisco
Career Start Year 2012
Number of shared co-authors 3
University of North Carolina School of Medicine
Career Start Year 2011
Number of shared co-authors 4
The Weizmann Institute of Science
Career Start Year 2007
Number of shared co-authors 11
University of Laval
Career Start Year 2007
Number of shared co-authors 2
St. Jude Children's Research Hospital
Career Start Year 2007
Number of shared co-authors 5
Center for the Development of Therapeutics, Broad Institute of MIT & Harvard
Career Start Year 2007
Number of shared co-authors 2
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 7
National Cancer Institute, National Institutes of Health
Career Start Year 2005
Number of shared co-authors 4
National Center for Advancing Translational Sciences, National Institutes of Health
Career Start Year 2002
Number of shared co-authors 7
University of Windsor
Career Start Year 2002
Number of shared co-authors 18
MedImmune Ltd.
Career Start Year 2001
Number of shared co-authors 2
Center for Cancer Research, National Cancer Institute
Career Start Year 2001
Number of shared co-authors 9
Career Start Year 2000
Number of shared co-authors 0
Institute for Neurodegenerative Diseases, University of California San Francisco
Career Start Year 2000
Number of shared co-authors 13
University of Dundee
Career Start Year 1999
Number of shared co-authors 8
Institute for Data Science and Computing, University of Miami
Career Start Year 1998
Number of shared co-authors 9
University of California San Francisco
Career Start Year 1997
Number of shared co-authors 2
Oncology R&D
Career Start Year 1997
Number of shared co-authors 2
University of Washington
Career Start Year 1996
Number of shared co-authors 2
Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai
Career Start Year 1996
Number of shared co-authors 6
Sirna Therapeutics a former subsidiary of Merck & Co., Inc.
Career Start Year 1994
Number of shared co-authors 2
The Walter and Eliza Hall Institute of Medical Research
Career Start Year 1993
Number of shared co-authors 4
Sunesis Pharmaceuticals, Inc. 395 Oyster Point Boulevard
Career Start Year 1993
Number of shared co-authors 4
Atux Iskay LLC
Career Start Year 1993
Number of shared co-authors 3
National Institutes of Health, National Center for Advancing Translational Sciences
Career Start Year 1992
Number of shared co-authors 3
University of Leeds
Career Start Year 1992
Number of shared co-authors 4
Vrije Universiteit Amsterdam (VU)
Career Start Year 1987
Number of shared co-authors 5
University of California berkeley
Career Start Year 1982
Number of shared co-authors 12
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California
Career Start Year 1981
Number of shared co-authors 12
Department of Pharmaceutical Chemistry, University of California San Francisco
Career Start Year 1974
Number of shared co-authors 10

Collaborators

Harvard Medical School
Co-authored papers 17
Institute for Biophysical Chemistry, Goethe-University
Co-authored papers 12
Botnar Research Centre, University of Oxford
Co-authored papers 12
University of Toronto
Co-authored papers 10
Sungkyunkwan University
Co-authored papers 8
University of Toronto
Co-authored papers 7
Co-authored papers 6
Lunenfeld-Tanenbaum Research Institute
Co-authored papers 5
Co-authored papers 4
UNC Chapel Hill School of Medicine
Co-authored papers 4
University of Georgia
Co-authored papers 3
Novo Nordisk Foundation Center for Protein Research, University of Copenhagen
Co-authored papers 3
University of Dundee
Co-authored papers 3
The University of Texas MD Anderson Cancer Center
Co-authored papers 3
The Institute of Cancer Research
Co-authored papers 3
University of Toronto, College St
Co-authored papers 3
Co-authored papers 3
Karolinska Institutet
Co-authored papers 3
Co-authored papers 3
University of Toronto
Co-authored papers 3
The University of Sheffield
Co-authored papers 3
Ludwig Institute for Cancer Research, University of Oxford
Co-authored papers 3
Dana-Farber Cancer Institute
Co-authored papers 3
Structural Genomics Consortium Karolinska Institute Stockholm Sweden.
Co-authored papers 3
University of California
Co-authored papers 3
Humboldt-Universitat zu Berlin
Co-authored papers 2
Institute of Molecular Medicine, Martin-Luther-University of Halle-Wittenberg
Co-authored papers 2
Ludwig Institute for Cancer Research Ltd.
Co-authored papers 2
The State University of New Jersey
Co-authored papers 2
University of Michigan ann arbor
Co-authored papers 2